The current research examines a novel method for the design of antibody-based drugs against G protein–coupled receptors (GPCRs), proteins involved in numerous physiological processes and often the targets of pharmacological intervention. GPCRs have traditionally been treated with small-molecule drugs; these, however, have the potential to produce unwanted side effects as a result of their lack of specificity. Although antibody-based drugs can potentially be a better option, their design for GPCR targeting is especially challenging as a result of the nature of these proteins.
The study investigates the feasibility, safety, and effectiveness of a high-intensity exercise programme for patients with hypertrophic cardiomyopathy (HCM). Historically, individuals with HCM were advised to avoid intense physical activity due to concerns about sudden cardiac death. However, recent research suggests that exercise might be safer than previously thought, prompting the need for further investigation.
Novo Nordisk has released the findings of its REDEFINE 2 trial, which compared the new weight loss drug, CagriSema, in adults with type 2 diabetes and overweight or obesity. CagriSema consists of two drugs, cagrilintide and semaglutide, aimed at suppressing hunger and weight loss.
The researchers set out to find out how over-time variation in insulin resistance (IR) may influence the development of cardiovascular disease (CVD). Researchers studied data from a large Chinese health survey and used two key markers to measure IR: the triglyceride-glucose (TyG) index and the TyG-BMI index (which combines TyG with body mass index).
This cross-sectional study by Sato et al. investigates the impact of Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors on nocturnal polyuria in type 2 diabetic patients, in particular on a comparison between the short-acting inhibitor tofogliflozin and other SGLT2 inhibitors. The sample was 142 patients, divided into two groups: one that received SGLT2 inhibitors and one that received none.
